Insight Molecular Diagnostics Inc. (IMDX) focuses on decentralizing molecular diagnostic testing for transplanted organ rejection, leveraging proprietary donor-derived cell-free DNA (dd-cfDNA) assays under the GraftAssure brand. The company offers LDT, RUO, and IVD products targeting hospitals and labs to enable in-house testing. Despite progress in product development and reimbursement coverage for certain tests, IMDX continues to operate at substantial net losses driven by investments in R&D and commercialization. Growth depends on FDA approval of IVD kits, expanded payer reimbursement, and navigating evolving regulatory frameworks around LDTs. The company maintains limited liquidity and negative equity, underscoring ongoing capital needs [F1][S1][S2][S19].